Literature DB >> 6999950

Malignant hyperthermia.

G A Gronert.   

Abstract

In MH, skeletal muscle acutely and unexpectedly increases its oxygen consumption and lactate production, resulting in greater heat production, respiratory and metabolic acidosis, muscle ridigity, sympathetic stimulation, and increased cellular permeability. The best-accepted theory is that MH is due to an inability to control calcium concentrations within the muscle fiber, and may involve a generalized alteration in cellular or subcellular membrane permeability. Episodes are predictably initiated in susceptible people and swine by potent volative anethetic agents or succinylcholine. In addition, in swine, MH is consistently triggered by excitement, apprehension, exercise, or environmental stress such as heat or hypoxia. Several genetic factors probably control the human and porcine inheritance of MH. Sympathetic involvement in MH, while controversial, is probably a response to stress that affects blood flow, heat loss, and myocardial function, rather than a direct sympathetic activation of susceptible muscle. Diagnosis is based upon extraordinary temperature and acid-base and muscle aberrations. Specific treatment is the action of dantrolene upon muscle calcium movements; sympatomatic treatment is by reversal of acid-base and temperature changes. Evaluation of affected families is guided by measurements of circulating creatine phosphokinase and by analysis of drug-induced contractures in muscle biopsy specimens. Anesthesia for susceptible patients includes thiopental, opiates, droperidol, pancuronium, nitrous oxide, and preoperative oral doses of dantrolene.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6999950     DOI: 10.1097/00000542-198011000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  75 in total

1.  Hyperkalaemic cardiac arrest in a manifesting carrier of Duchenne muscular dystrophy following general anaesthesia.

Authors:  T P Kerr; A Duward; S V Hodgson; E Hughes; S A Robb
Journal:  Eur J Pediatr       Date:  2001-09       Impact factor: 3.183

2.  Greater than normal variability of Ca-induced Ca release in muscle fibers of a patient with a positive family history of malignant hyperthermia.

Authors:  K Maruyama; M Yamagiwa; K Nishimura; K Konishi; M Muneyuki
Journal:  J Anesth       Date:  1992-10       Impact factor: 2.078

3.  Postanesthetic malignant hyperthermia with convulsions.

Authors:  T Arai; K Dote; K Nitta; I Tsukahara
Journal:  J Anesth       Date:  1987-09-01       Impact factor: 2.078

4.  TENS-induced pain control in a malignant hyperthermia-susceptible patient.

Authors:  W Stenberg
Journal:  Anesth Prog       Date:  1994

5.  Effects of the 5-HT2 receptor antagonist ritanserin on halothane-induced increase of inositol phosphates in porcine malignant hyperthermia.

Authors:  A Richter; J Scholz; W Löscher; P H Tonner; F Wappler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

6.  Sensibilité à l'halothane dans quelques élevages de porcs Landrace au Québec.

Authors:  A M Lafortune; D Malo; S Nadeau; L Deroth
Journal:  Can Vet J       Date:  1989-01       Impact factor: 1.008

Review 7.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

8.  Diverse forms of stress lead to new patterns of gene expression through a common and essential metabolic pathway.

Authors:  G L Hammond; Y K Lai; C L Markert
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

Review 9.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

10.  Neuroleptic malignant syndrome: a case for electroconvulsive therapy.

Authors:  C C Harland; M M O'Leary; R Winters; J Owens; B Hayes; V Melikian
Journal:  Postgrad Med J       Date:  1990-01       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.